Peijia Medical Limited

Peijia Medical Limited

4WO · F · Healthcare / Medical Devices

0.414EUR-0.01 (-3.27%)

Price History

Full chart

Market Stats

Previous Close0.428
Open0.414
Day Range0.414 – 0.414
52-Week Range0.394 – 0.775
Volume0
Market Cap330.43M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.03
Dividend Yield0.00%
Beta0.62
50-Day Avg0.5048
200-Day Avg0.5711

About

Peijia Medical Limited, together with its subsidiaries, engages in the research, development, manufacturing, and sales of transcatheter valve therapeutic and neurointerventional procedural medical devices in the People's Republic of China. It operates through Transcatheter Valve Therapeutic Business, Neurointerventional Business, and Future Technology Business segments. The company's products include transcatheter aortic valve replacement (TAVR) systems, crosslinked dry-tissue and polymeric tri leaflet TAVR systems, transcatheter aortic valve systems, lithotripsy valvuloplasty technology and interventional robotics technology, transseptal mitral valve replacement systems, transfemoral balloon catheter, introducer sheath, pre-shaped guidewire, detachable coils, balloon guide catheter, aspiration catheter, stent retriever, delivery balloon dilatation catheter, balloon dilatation catheter, microcatheter, micro guidewire, micro guidewire, guide catheter, distal access guide catheter, intermediate catheter, and power supply. In addition, it engages in the trading and holding business. Peijia Medical Limited was incorporated in 2012 and is headquartered in Suzhou, the People's Republic of China.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEODr. Yi Zhang
  • Employees1.03K
  • HeadquartersNo.18 Yangjiatian Road, Suzhou, China, 215028, Germany
  • Websitehttps://www.peijiamedical.com

Leadership

  • Dr. Yi ZhangChairman & CEO · b. 1968
  • Mr. Lieh TsaiChief Financial Officer · b. 1980
  • Mr. Kongrong PanChief Operating Officer · b. 1959
  • Dr. Fong Tan JianChief Technology Officer · b. 1976
  • Ms. Ping Ye ZhangExecutive Director · b. 1968
  • Ms. Hong YeExecutive Director & Company Secretary · b. 1972
  • Ms. Xiaoxiao ZhuangVice President of Sales · b. 1983
  • Ms. Hongpeng WangVice President of Marketing · b. 1981
  • Ms. Hing Ling Chau FCIS, FCS, L.L.M.Company Secretary · b. 1975

Financials

Income Statement

Currency: CNY2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue018.70M38.66M136.53M250.83M441.13M615.48M712.87M
Growth (%)--+106.72%+253.21%+83.71%+75.86%+39.53%+15.82%
Cost of Revenue06.69M13.43M40.88M74.63M115.76M181.86M226.82M
Gross Profit012.01M25.22M95.65M176.20M325.37M433.62M486.05M
Gross Margin-64.24%65.25%70.06%70.25%73.76%70.45%68.18%
Operating Expense71.66M234.38M234.49M645.26M727.92M741.20M663.92M681.36M
Operating Income-71.66M-222.37M-209.26M-549.60M-551.72M-415.83M-230.30M-195.31M
Operating Margin--1189.21%-541.37%-402.54%-219.96%-94.27%-37.42%-27.40%
EBITDA-77.94M-517.82M-2.07B-574.03M-359.90M-348.52M-157.81M-123.01M
EBITDA Margin--2769.21%-5351.35%-420.43%-143.48%-79.01%-25.64%-17.26%
Net Income-82.63M-531.98M-2.07B-574.22M-407.81M-392.52M-226.58M-203.29M
Net Income Margin--2844.95%-5351.59%-420.57%-162.58%-88.98%-36.81%-28.52%
R&D27.85M55.13M103.36M445.88M373.13M293.42M203.42M254.36M
R&D as % of Total Revenue-294.85%267.40%326.57%148.76%66.52%33.05%35.68%
Interest Expense163.00K823.00K91.00K186.00K2.32M178.00K4.74M11.73M
Interest Expense % of Total Revenue-4.40%0.24%0.14%0.92%0.04%0.77%1.65%

Balance Sheet

Currency: CNY2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets174.36M879.48M2.88B3.16B3.32B2.67B2.69B2.66B
Total Liabilities268.70M1.44B67.99M144.48M678.86M397.88M644.11M798.71M
Total Equity-94.34M-558.21M2.81B3.02B2.64B2.27B2.03B1.84B
Cash94.76M504.63M2.46B2.30B1.67B795.77M666.74M536.73M

Cash Flow

Currency: CNY2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-38.73M-102.59M-181.10M-436.37M-376.20M-630.91M-5.18M-20.89M
Investing Cash Flow-8.38M31.96M-12.48M-----
Financing Cash Flow104.43M475.74M2.34B-----
Capital Expenditure8.10M13.47M25.25M201.34M202.34M316.19M280.11M304.39M
Free Cash Flow-47.11M-116.12M-209.04M-637.71M-578.54M-947.10M-285.29M-325.28M
FCF to OCF121.65%113.18%115.43%146.14%153.79%150.12%5507.45%1556.98%

Key Statistics & Ratios

Market Cap330.43M
Enterprise Value358.35M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.42
Price / Book1.48
EPS-0.03
Book Value0.3629
Revenue (TTM)783.99M
Gross Profit (TTM)528.47M
EBITDA-31.97M
Profit Margin-17.98%
Operating Margin8.00%
Return on Equity-7.60%
Return on Assets-2.20%
Shares Outstanding668.88M
Shares Float419.40M
Beta0.62
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%